Elsevier

Diabetes & Metabolism

Volume 42, Issue 3, June 2016, Pages 142-156
Diabetes & Metabolism

Review
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

https://doi.org/10.1016/j.diabet.2016.04.002Get rights and content

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10Ā years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.

Introduction

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver pathology including simple steatosis, non-alcoholic steatohepatitis (NASH) with varying amounts of fibrosis and cirrhosis [1]. NAFLD has emerged as a public health problem of epidemic proportions in many parts of the world (affecting up to 30% of the adult population in the United States and Europe) [1], [2]. The prevalence of NAFLD is much higher in patients with type 2 diabetes (ranging from approximately 50 to 75%). Notably, patients with type 2 diabetes and NAFLD are also more likely to develop the more severe forms of NAFLD, such as NASH, advanced fibrosis, cirrhosis, and in some cases hepatocellular carcinoma [1], [2].

Over the past decade, it has become increasingly clear that NAFLD is not only associated with an increased risk of liver-related morbidity or mortality, but also it is a multisystem disease that affects a variety of extra-hepatic organ systems, and interacts with the regulation of multiple metabolic pathways [3]. Strong evidence indicates that cardiovascular disease is the leading cause of mortality in patients with NAFLD [3], [4]. As detailed below, there is now also convincing evidence suggesting that NAFLD may often precede the development of type 2 diabetes. This supports the assertion that the conventional paradigm of NAFLD representing the simple ā€œhepatic manifestationā€ of the metabolic syndrome is outdated, and that NAFLD might be regarded as an early predictor and determinant for the development of diabetes and other clinical traits of the metabolic syndrome [5]. This finding may have potentially relevant clinical implications for the diagnosis, prevention and treatment of type 2 diabetes.

Specifically, in this narrative review we discuss the rapidly expanding body of clinical evidence that supports a strong association between NAFLD and the risk of new-onset type 2 diabetes, and the putative biological mechanisms underlying this association. We also briefly discuss some of the treatment options for NAFLD that may influence the risk of diabetes.

To this end, although this is not a formal systematic review, we extensively searched PubMed database to identify relevant articles published up to January 2016, using the keywords ā€œnon-alcoholic fatty liver diseaseā€ or ā€œfatty liverā€ combined with ā€œincident type 2 diabetesā€ or ā€œdiabetes riskā€.

Section snippets

Epidemiological evidence linking NAFLD to the risk of new-onset type 2 diabetes

In this review, we have not discussed the large number of prospective, population-based studies that used serum levels of liver enzymes (or other surrogate markers of NAFLD such as the fatty liver index) to diagnose NAFLD. These studies have consistently shown that mildly elevated serum liver enzymes (mainly serum gamma-glutamyltransferase) are independent, long-term predictors of new-onset type 2 diabetes in various ethnic populations (Asian, American and European people) [6], [7], [8].

Data

Putative biological mechanisms by which NAFLD contributes to diabetes development

When imbalance occurs between energy intake and energy expenditure, or when there is an intrinsic problem with storing excess energy as tri-acylglycerol in adipose tissue depots, lipid accumulates in other organs throughout the body. If lipid accumulates in tissues or organs not designed to accumulate fat, e.g., liver or omentum, the term ā€˜ectopic fat accumulationā€™ infers that lipid accumulation has occurred in a non physiological site with the potential for increasing risk of certain common

Treatment options for NAFLD that may influence risk of type 2 diabetes

The past decade has been characterized by an intensive search of effective treatments for NAFLD, fostered by the evidence of a significant burden of disease for all national healthcare systems. Behavioural changes, including dietary restriction and increased physical activity, and drug therapy are the pillars of NAFLD treatment. The assessment of their effects on the risk of disease progression has been limited by several factors:

  • ā€¢

    the lack of valid surrogate markers, making liver biopsy

Conclusions

In this updated review of the published studies, we provide further support for the strong association between NAFLD and increased risk of new-onset type 2 diabetes, though causality remains to be proven in well-controlled prospective and intervention studies. Future studies are also needed to assess the potential added value of using the presence of NAFLD to predict the risk of incident type 2 diabetes beyond that provided by common risk factors for diabetes. Finally, in the presence of NAFLD,

Author contributions

GT conceived and designed the study. GT, GM and CDB researched data and wrote the manuscript.

Disclosure of interest

The authors declare that they have no competing interest.

Acknowledgments

GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. CDB is supported in part by the Southampton National Institute for Health Research Biomedical Research Centre.

References (91)

  • G.S. Hotamisligil

    Endoplasmic reticulum stress and the inflammatory basis of metabolic disease

    Cell

    (2010)
  • H. Tilg et al.

    Insulin resistance, inflammation, and non-alcoholic fatty liver disease

    Trends Endocrinol Metab

    (2008)
  • K.G. Kumar et al.

    Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism

    Cell Metab

    (2008)
  • Y. Oike et al.

    Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy

    Trends Mol Med

    (2005)
  • H. Misu et al.

    A liver-derived secretory protein, selenoprotein P, causes insulin resistance

    Cell Metab

    (2010)
  • R.C. Meex et al.

    Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism

    Cell Metab

    (2015)
  • M.J. Armstrong et al.

    Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

    Lancet

    (2016)
  • V. Ratziu et al.

    Current efforts and trends in the treatment of NASH

    J Hepatol

    (2015)
  • N. Mazzella et al.

    The role of medications for the management of patients with NAFLD

    Clin Liver Dis

    (2014)
  • G. Lassailly et al.

    Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients

    Gastroenterology

    (2015)
  • V. Ratziu et al.

    Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

    Gastroenterology

    (2008)
  • G.P. Aithal et al.

    Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

    Gastroenterology

    (2008)
  • S.H. Caldwell et al.

    A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

    Am J Gastroenterol

    (2001)
  • J.L. Chiasson et al.

    Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

    Lancet

    (2002)
  • M.J. Armstrong et al.

    Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

    J Hepatol

    (2016)
  • A. Gastaldelli et al.

    Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

    J Hepatol

    (2016)
  • M.E. Rinella

    Nonalcoholic fatty liver disease: a systematic review

    JAMA

    (2015)
  • A. Lonardo et al.

    Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups

    Dig Liver Dis

    (2015)
  • G. Targher et al.

    Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

    N Engl J Med

    (2010)
  • A. Fraser et al.

    Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis

    Diabetes Care

    (2009)
  • G. Musso et al.

    natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

    Ann Med

    (2011)
  • S. Ballestri et al.

    Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

    J Gastroenterol Hepatol

    (2015)
  • M. Okamoto et al.

    The association of fatty liver and diabetes risk

    J Epidemiol

    (2003)
  • J.G. Fan et al.

    Effects of nonalcoholic fatty liver disease on the development of metabolic disorders

    J Gastroenterol Hepatol

    (2007)
  • M. Shibata et al.

    Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men

    Diabetes Care

    (2007)
  • C.H. Kim et al.

    Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults

    Diabet Med

    (2008)
  • T. Yamada et al.

    Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup

    J Gastroenterol Hepatol

    (2010)
  • J.C. Bae et al.

    Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study

    Diabetes Care

    (2011)
  • S.K. Park et al.

    Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study

    Hepatology

    (2013)
  • K.C. Sung et al.

    Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes

    Diabetes Care

    (2012)
  • A. Kasturiratne et al.

    Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus

    J Gastroenterol Hepatol

    (2013)
  • Y. Chang et al.

    Cohort study of non-alcoholic fatty liver disease. NAFLD fibrosis score, and the risk of incident diabetes in a Korean population

    Am J Gastroenterol

    (2013)
  • K.C. Sung et al.

    Resolution of fatty liver and risk of incident diabetes

    J Clin Endocrinol Metab

    (2013)
  • H. Yamazaki et al.

    Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes

    Diabetes Care

    (2015)
  • T. Fukuda et al.

    The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals

    Liver Int

    (2016)
  • Cited by (0)

    View full text